Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.52 |
| ▸ | CTSD | P07339 | 8/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28086038 | 0.88 | MAP4K4 (0.43) | BACE1CTSDMAP4K4ALDH1A1 | |
| SCHEMBL5022826 | 0.86 | ALDH1A1 (0.51) | BACE1CTSDALDH1A1 | |
| SCHEMBL19008149 | 0.85 | ALDH1A1 (0.46) | BACE1CTSDMAP4K4ALDH1A1 | |
| SCHEMBL19008153 | 0.83 | ALDH1A1 (0.56) | BACE1CTSDALDH1A1 | |
| SCHEMBL18626538 | 0.83 | ALDH1A1 (0.60) | BACE1CTSDALDH1A1 | |
| SCHEMBL20803950 | 0.81 | SMN1; SMN2 (0.44) | ALDH1A1 | |
| SCHEMBL19008166 | 0.81 | BACE1 (0.47) | BACE1CTSDMAP4K4ALDH1A1BCHE | |
| SCHEMBL19008147 | 0.81 | ALDH1A1 (0.47) | BACE1CTSDALDH1A1 | |
| SCHEMBL19016216 | 0.80 | MAP4K4 (0.44) | BACE1MAP4K4ALDH1A1BCHE | |
| SCHEMBL15587412 | 0.80 | ACHE (0.56) | BACE1MAP4K4ALDH1A1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855269-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | FLT4, FLT1, KDR | BACE1 3929/4885CTSD 3865/4885MAP4K4 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.